Precigen (PGEN) director converts 71,839 RSUs into common stock, now holding 305,776 shares

Rhea-AI Filing Summary

PRECIGEN, INC. director Nancy H. Agee exercised restricted stock units that converted into common shares. On March 13, 2026, 71,839 RSUs vested in full, with each RSU representing one share of Precigen common stock. Following the conversion, she directly holds 305,776 shares of common stock.

This is a compensation-related equity vesting rather than an open-market purchase or sale, and there were no shares reported as sold in connection with this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGEE NANCY H

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		M		71,839	A	(1)	305,776	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		M			71,839	(2)	(2)	Common Stock	71,839	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vested in full on March 13, 2026.

	/s/ Nancy H. Agee, by Donald P. Lehr, as attorney-in-fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Precigen (PGEN) report for Nancy H. Agee?

Precigen reported that director Nancy H. Agee exercised 71,839 restricted stock units into common shares. The RSUs vested in full on March 13, 2026, increasing her direct common stock holdings to 305,776 shares after the transaction.

How many Precigen (PGEN) RSUs did Nancy H. Agee exercise?

Nancy H. Agee exercised 71,839 restricted stock units in Precigen. Each RSU represented a right to receive one share of common stock, so 71,839 new common shares were issued to her when the awards vested in full on March 13, 2026.

Did Nancy H. Agee sell any Precigen (PGEN) shares in this Form 4?

No shares were reported as sold in this Form 4. The filing shows an exercise and conversion of 71,839 restricted stock units into common stock, with no sale transactions, leaving her with 305,776 directly owned common shares after the event.

What is Nancy H. Agee’s Precigen (PGEN) share ownership after the RSU vesting?

After the RSUs vested and converted, Nancy H. Agee directly owns 305,776 shares of Precigen common stock. This total reflects the addition of 71,839 shares received from restricted stock units that vested in full on March 13, 2026.

What do the restricted stock units in Precigen’s (PGEN) Form 4 represent?

Each Precigen restricted stock unit represents a contingent right to receive one share of common stock. In this filing, 71,839 RSUs vested in full on March 13, 2026 and were converted into an equal number of common shares for director Nancy H. Agee.

Is the Precigen (PGEN) Form 4 for Nancy H. Agee an open-market trade?

This Form 4 reflects a derivative exercise of restricted stock units, not an open-market trade. The transaction shows 71,839 RSUs vesting and converting into common stock at a stated price of $0.00 per share, with no concurrent market sale reported.